LYT-200

LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, received FDA Fast Track designation for AML treatment, showing promise in Phase 1/2 trials for AML/MDS and head and neck cancers. It targets galectin-9, demonstrating potential in killing cancer cells and reactivating the immune system.

PureTech Health PLC's LYT-200 antibody received FDA fast track designation for AML treatment, aiming to expedite development for serious conditions. LYT-200 targets galectin-9, inducing cancer cell death and reactivating the immune system, currently in phase 1 and 2 trials. Shares rose 6.9%.

PureTech Health's LYT-200, an anti-galectin-9 monoclonal antibody, received FDA Fast Track designation for AML treatment, aiming to expedite drug development for serious conditions. LYT-200 targets cancer cells through apoptosis, DNA damage, and immune system reactivation, with ongoing clinical trials and additional Fast Track designation for head and neck cancers.

PureTech Health's LYT-200, an anti-galectin-9 monoclonal antibody, received FDA Fast Track designation for treating acute myeloid leukemia and recurrent/metastatic head and neck squamous cell carcinomas, alongside orphan drug designation for AML. Development will proceed through Gallop Oncology.

PureTech Health's LYT-200, an anti-galectin-9 monoclonal antibody, received FDA Fast Track designation for AML treatment, highlighting its potential in killing cancer cells and reactivating the immune system. Currently in Phase 1/2 trials, LYT-200 shows promise with favorable safety and early clinical activity, aiming to address the urgent need for new AML therapies.

LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, received FDA Fast Track designation for AML treatment, showing promise in Phase 1/2 trials for AML/MDS and head and neck cancers. It targets galectin-9, offering a novel approach by killing cancer cells and reactivating the immune system.

LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, received FDA Fast Track designation for AML treatment, showing promise in Phase 1/2 trials for AML/MDS and head and neck cancers. It targets galectin-9, demonstrating potential in cancer cell apoptosis and immune system reactivation, with favorable safety and early clinical activity signals.